Finance entity
The clearest coverage concentration is markets: 4 of 6 stories, with the rest divided among 1 other category. Against the same-window beat baseline of 28% negative, this entity's 0% share is less negative. Source depth averages 2.2 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is markets: 4 of 6 stories, with the rest divided among 1 other category. Against the same-window beat baseline of 28% negative, this entity's 0% share is less negative. Source depth averages 2.2 original sources per story, versus 2.8 across the same-window beat baseline. Pfizer is most often covered alongside Bristol Myers Squibb, which appears in 2 of these 6 stories. The 165-day window averages about 0.3 stories each week. Their average consequence score of 6 runs below the beat's 6.3 for that window. We currently track 6 Finance stories that mention Pfizer, published between February 19, 2026 and August 2, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 3876 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pfizer. Shared-story counts are live from our verified record — not editorial picks.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
With a 6.9% yield (vs 1% for the S&P 500) and a 130% payout ratio, Pfizer presents a classic risk-reward scenario for income portfolios. The stock’s 60% decline from 2021 highs prices in significant pessimism, but historical resilience may offer patient investors a favorable entry.
Seeking Alpha's post-earnings quant ratings for stocks above $10B market cap reveal a stark divergence between innovation-led growth and legacy value traps. While GLP-1 leaders and AI-driven ad platforms dominate the top rankings, traditional pharma and media outlets struggle with growth revisions and margin compression.
Tarsus Pharmaceuticals and ORIC Pharmaceuticals reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial scaling and clinical data maturation. While Tarsus focuses on the rapid adoption of XDEMVY, ORIC is advancing its oncology pipeline with key data readouts expected in 2026.
Health experts and economists are advocating for a subscription-based 'Netflix' model for antibiotics to combat the rise of superbugs. This proposed shift aims to decouple pharmaceutical profits from sales volume, incentivizing R&D in a sector currently plagued by market failure.
Pfizer is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
